Dosage ;
Usual Dose = 100-1600 mg daily.
Children: 10-20mg/kg daily depending on severity of illness and indication.
A tricyclic iminostilbene derivative
Specific Dosages;
Dosing: Adult
Dosage must be adjusted according to patient's response and serum concentrations. Administer tablets (chewable or conventional) in 2-3 divided doses daily and suspension in 4 divided doses daily. Oral:
Epilepsy: Initial: 400 mg/day in 2 divided doses (tablets or extended release tablets) or 4 divided doses (oral suspension); increase by up to 200 mg/day at weekly intervals using a twice daily regimen of extended release tablets or capsules, or a 3-4 times/day regimen of other formulations until optimal response and therapeutic levels are achieved; usual dose: 800-1200 mg/day
Maximum recommended dose: 1600 mg/day; however, some patients have required up to 1.6-2.4 g/day
Trigeminal or glossopharyngeal neuralgia: Initial: 200 mg/day in 2 divided doses (tablets, extended release tablets, or extended release capsules) or 4 divided doses (oral suspension) with food, gradually increasing in increments of 200 mg/day as needed.
Maintenance: Usual: 400-800 mg daily in 2 divided doses (tablets, extended release tablets, or extended release capsules) or 4 divided doses (oral suspension); maximum dose: 1200 mg/day
Bipolar disorder: Initial: 400 mg/day in 2 divided doses (tablets, extended release tablets, or extended release capsules) or 4 divided doses (oral suspension), may adjust by 200 mg/day increments; maximum dose: 1600 mg/day.
Dosing: Pediatric
Dosage must be adjusted according to patient's response and serum concentrations. Administer tablets (chewable or conventional) in 2-3 divided doses daily and suspension in 4 divided doses daily.
Epilepsy: Oral:
Children <6 years: Initial: 10-20 mg/kg/day divided twice or 3 times daily as tablets or 4 times/day as suspension; increase dose every week until optimal response and therapeutic levels are achieved
Maintenance dose: Divide into 3-4 doses daily (tablets or suspension); maximum recommended dose: 35 mg/kg/day
Children 6-12 years: Initial: 200 mg/day in 2 divided doses (tablets or extended release tablets) or 4 divided doses (oral suspension); increase by up to 100 mg/day at weekly intervals using a twice daily regimen of extended release tablets or 3-4 times daily regimen of other formulations until optimal response and therapeutic levels are achieved
Maintenance: Usual: 400-800 mg/day; maximum recommended dose: 1000 mg/day
Note: Children <12 years who receive ≥400 mg/day of carbamazepine may be converted to extended release capsules (Carbatrol®) using the same total daily dosage divided twice daily
Children >12 years: Refer to adult dosing.
Maximum recommended doses:
Children 12-15 years: 1000 mg/day
Children >15 years: 1200 mg/day
Dosing: Geriatric
Refer to adult dosing.
Dosing: Renal Impairment
Dosage adjustments are not required or recommended in the manufacturer’s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):
Children and Adults:
GFR <10 mL/minute: Administer 75% of dose.
Hemodialysis, peritoneal dialysis: Administer 75% of dose.
Continuous renal replacement therapy (CRRT):
Children: Administer 75% of dose.
Adults: No dosage adjustment recommended.
Dosing: Hepatic Impairment
Use with caution in hepatic impairment; metabolized primarily in the liver
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Azepine | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 200mg | 100 | Tablet | per tablet | KES 200.00 |
| Azepine | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 200mg | 1000 | Tablet | per tablet | KES 1,700.00 |
| Azepine | Biodeal Laboratories Ltd. | Biodeal Laboratories Ltd. | 200mg | 500 | Tablet | per tablet | KES 1,000.00 |
| Carbamazepine | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 200mg | 100 | Tablet | per tablet | KES 200 |
| Carbamazepine | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 200mg | 1000 | Tablet | per tablet | KES 1,400 |
| Carbatol | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 200mg | 100 | Tablet | per tablet | KES 270.00 |
| Carbatol | Torrent Pharmaceuticals Ltd. | Medox Pharmaceuticals Ltd. | 200mg | 1000 | Tablet | per tablet | KES 2,650.00 |
| Carbazin | Eskayef Bangladesh Limited | Umoja Pharmaceutical s Limited. | 200mg | 50 | Tablet | per tablet | KES 1,351.00 |
| Carbazina | Flamingo Heat Pad | Harley's Limited | 200mg | 100 | Tablet | per tablet | KES 225.00 |
| Carbazina | Flamingo Heat Pad | Harley's Limited | 200mg | 1000 | Tablet | per tablet | KES 1,200.00 |
| Eptol | Cosmos Limited. | Cosmos Limited | 200mg | 100 | Tablet | per tablet | KES 450.00 |
| Labtol | Laboratory & Allied Ltd. | Laboratory & Allied Ltd | 200mg | 1000 | Tablet | per tablet | KES 1,800.00 |
| Neurotrol | Universal Pharmaceuticals Ltd. | Europa Healthcare Ltd. | 200mg | 100 | Tablet | per tablet | KES 228.00 |
| Neurotrol | Universal Pharmaceuticals Ltd. | Europa Healthcare Ltd. | 200mg | 1000 | Tablet | per tablet | KES 2,070.00 |
| Taver | Medochemie | Omaera Pharmaceuticals Ltd | 200mg | 50 | Tablet | per tablet | KES 250.00 |
| Tegretol | Novartis Consumers | Harley's Limited | 100mg | 50 | Tablet | per tablet | KES 1,092.30 |
| Tegretol | Novartis Consumers | Harley's Limited | 200mg | 50 | Tablet | per tablet | KES 1,684.00 |
| Tegretol | Novartis Consumers | Harley's Limited | 200mg | 500 | Tablet | per tablet | KES 12,521.00 |
| Tegretol | Novartis Consumers | Harley's Limited | 200mg | 50 | Tablet | per tablet | KES 1,684.00 |
| Tegretol | Novartis Consumers | Harley's Limited | 400mg | 30 | Tablet | per tablet | KES 1,755.00 |
| Tegretol | Novartis Consumers | Harley's Limited | 20mg | 100ml | Syrup | per 5ML | KES 820.00 |
| Tegretol | Novartis Consumers | Harley's Limited | 2mg | 100ml | Syrup | per 5ML | KES 653.00 |
| Zen | Intas Pharmaceuticals Ltd | Unicorn Pharma (K) Ltd. | 200mg | 1000 | Tablet | per tablet | KES 2,000.00 |
| Zeptol | Sunlight International Trading (Africa) Co., Ltd | Harley's Limited | 200mg | 100 | Tablet | per tablet | KES 1,360.00 |
| Progretaz | Prism Life Sciences | Galaxy Pharmaceuticals Ltd | 200mg | 100 | Tablet | per tablet | KES 210.00 |
| Carbamazepine More info | |
|---|---|
| Mode Of Action | Carbamazepine: Anticonvulsant action - the exact mechanism is unknown and possibilities may include: acting postsynaptically by limiting the ability of neurons to sustain high frequency repetitive firing of action potentials through enhancement of sodium channel inactivation, altering neuronal excitability, blocking the release of neurotransmitter by blocking presynaptic sodium channels and the firing of action potentials, which in turn decreases synaptic transmission. Antineuralgic - the exact mechanism is unknown and possibilities may include; involvement of gamma-aminobutyric acid (GABA) receptors, which may be linked to calcium channels.Antidiuretic: the exact mechanism is unknown and possibilities may include: exerting a hypothalamic effect on the osmoreceptors mediated via secretion of antidiuretic hormone (ADH), direct effect on the renal tubule. |
| Drug Indication | All forms of epilepsy except absence seizures; prophylaxis in maniac depressive disorders in patients who are unresponsive to, or cannot tolerate lithium or neuroleptics alone; in alcohol withdrawal syndrome; trigeminal neuralgia; idiopathic glossopharyngeal neuralgia; diabetic neuropathy and diabetes insipidus. |
| Precautions | Not to be used in absence seizures; in case of cardiac, hepatic and renal damage; monitor liver functions. |
| Contra-Indications | History of bone marrow depression; hypersensitivity to carbamazepine and tricyclic anti-depressants; concomitant use with MAO inhibitors |
| Side Effects | Dizziness; water retention and dilutional hyponatremia (due to induced stimulation of ADH); ataxia; GIT disturbances; drowsiness; headache; visual disturbances; anorexia; constipation; erythematous rashes; blood disorders; Steven-Johnson Syndrome; alopecia. |
| Dosage | 100-1600 mg daily. Children: 10-20mg/kg daily depending on severity of illness and indication. |
| Special Information | A tricyclic iminostilbene derivative |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Anticonvulsants |